InvestorsHub Logo
Followers 3
Posts 117
Boards Moderated 0
Alias Born 02/16/2015

Re: None

Friday, 05/19/2017 12:06:45 PM

Friday, May 19, 2017 12:06:45 PM

Post# of 3707
Closed an exclusive North American license agreement with AMAG Pharmaceuticals to develop and commercialize bremelanotide in February 2017.
Received $60 million upfront payment
Working closely with AMAG on completing the tasks and activities necessary to file a New Drug Application (NDA) with the Food and Drug Administration (FDA).
Target NDA filing with the FDA for the first quarter of calendar year 2018.
AMAG paying the bills to move Bremelanotide forward to an NDA.
Also PTN receiving milestone payments along the way.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PTN News